New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...